Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -59.32% | -24.80% | -57.45% | -63.02% | -22.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.32% | -24.80% | -57.45% | -63.02% | -22.46% |
| Cost of Revenue | -7.18% | -3.71% | -20.53% | -20.03% | -6.43% |
| Gross Profit | -29.82% | -12.77% | -68.36% | -3.62% | -9.66% |
| SG&A Expenses | -4.18% | -18.66% | -18.22% | -22.25% | -9.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.48% | -7.08% | -19.99% | -20.51% | -7.23% |
| Operating Income | -18.15% | -2.04% | -24.46% | 4.17% | -2.11% |
| Income Before Tax | 8.58% | 1.21% | -53.53% | 0.82% | -48.52% |
| Income Tax Expenses | 102.81% | 88.89% | 102.00% | -- | -144.31% |
| Earnings from Continuing Operations | 3.72% | -8.63% | -85.38% | 0.43% | -21.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.72% | -8.63% | -85.38% | 0.43% | -21.27% |
| EBIT | -18.15% | -2.04% | -24.46% | 4.17% | -2.11% |
| EBITDA | -20.38% | -2.36% | -26.35% | 4.67% | -0.88% |
| EPS Basic | 4.16% | -6.93% | -82.74% | 43.15% | 88.93% |
| Normalized Basic EPS | -28.11% | -7.88% | -41.49% | 43.37% | 90.37% |
| EPS Diluted | 4.16% | -6.93% | -82.74% | 43.15% | 88.93% |
| Normalized Diluted EPS | -28.11% | -7.88% | -41.49% | 43.37% | 90.37% |
| Average Basic Shares Outstanding | 0.45% | 1.59% | 1.45% | 75.13% | 995.76% |
| Average Diluted Shares Outstanding | 0.45% | 1.59% | 1.45% | 75.13% | 995.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |